Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01443325
Other study ID # H-2-2011-051
Secondary ID
Status Completed
Phase Phase 3
First received September 26, 2011
Last updated June 21, 2012
Start date September 2011
Est. completion date June 2012

Study information

Verified date June 2012
Source Rigshospitalet, Denmark
Contact n/a
Is FDA regulated No
Health authority Denmark: Danish Medicines AgencyDenmark: Danish Dataprotection Agency
Study type Interventional

Clinical Trial Summary

In the present placebo-controlled cross-over study the researchers intend to investigate analgesic and sensory effects of a lidocaine patch in patients with severe persistent inguinal post-herniorrhaphy pain.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date June 2012
Est. primary completion date June 2012
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Males > 18 yrs

- ASA (American Society´s of Anesthesiology´s classification) scores I-III, with severe Pain for more than six months and with average daily pain intensities (numerical rating scale [NRS] 0-10 points) during rest or during movement > 6.

Exclusion Criteria:

- History of an allergic reaction or intolerance to amide local anesthetics or vehicle ingredients in the patches

- Use of class I antiarrhythmic drugs (e.g., tocainide and mexiletine)

- Severe cardiac impairment, e.g., NYHA (New York Heart Association) Class = III

- Inflamed or injured skin at the application site

- Known severe hepatic disorder (Child-Pugh score > 6)

- Known severe renal impairment, (creatinine clearance < 30 mL/min)

- Signs of cognitive impairment or known drug or ethanol abuse during the last 2 years.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
lidocaine patch
1 patch for 12 hours within each 24 hours period

Locations

Country Name City State
Denmark Rigshospitalet Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary pain reduction with lidocaine patch assessed the last three days in each treatment period No